AI Article Synopsis
- re! Please provide the text you would like me to summarize.
Article Abstract
.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01443615.2022.2141616 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.
J Exp Clin Cancer Res
December 2024
Department of Oncology, Molecular Biotechnology Center "G. Tarone", University of Torino, Piazza Nizza 44, Torino, 10126, Italy.
Background: Malignant pleural mesothelioma (MPM) is a highly chemo-refractory and immune-evasive tumor that presents a median overall survival of 12-14 months when treated with chemotherapy and immunotherapy. New anti-tumor therapies as well as the concomitant reactivation of immune destruction are urgently needed to treat patients with this tumor. The aim of this work is to investigate the potential effect of ecteinascidin derivatives as lurbinectedin as new first-line treatment option in MPM, alone and in combination with immunotherapy.
View Article and Find Full Text PDFAmerican Association of Bronchology and Interventional Pulmonology Essential Knowledge in Interventional Pulmonology Series: Selected Topics in Malignant Pleural Disease.
J Bronchology Interv Pulmonol
January 2025
Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Article Synopsis
- The American Association of Bronchology and Interventional Pulmonology aims to keep clinicians informed with brief, current reviews on essential interventional pulmonology topics, starting with malignant pleural disease.
- The article consists of three parts that update readers on malignant pleural effusion: diagnosis through imaging and fluid biomarkers, management strategies including multimodal approaches and targeted therapies, and details on pleural mesothelioma.
- These reviews are part of the Essential Knowledge series presented at the 2023 AABIP Annual Conference, and recorded lectures are available for access on the AABIP website.
Imaging, pathological and molecular detection of malignant peritoneal mesothelioma (MPM): a case description.
Quant Imaging Med Surg
December 2024
Department of Geriatrics, Peking University First Hospital, Beijing, China.
Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobe .
Front Chem
December 2024
Medical Imaging Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Objectives: Immune checkpoint inhibitors (ICIs) have demonstrated potential in inhibiting the growth of malignant pleural mesothelioma (MPM), and their efficacy is associated with the expression of programmed death-ligand 1(PD-L1). This study evaluated a PD-L1-targeted nanoprobe for detecting PD-L1 expression in a nude mouse model of malignant pleural mesothelioma (MPM).
Methods: A PD-L1-binding peptide (WL-12) was conjugated with superparamagnetic iron oxide nanoparticles (SPIONs) to create the nanoprobe WL-12@Fe₃O₄.
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma.
Front Immunol
December 2024
Department of Oncology, Oslo University Hospital, Oslo, Norway.
Background: Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival, but the rate of immune-related adverse events (irAEs) is high. Serum cytokines reflect systemic immune reactions and may serve as biomarkers for irAEs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!